Cell Line Development

Curia offers advanced methods to rapidly move programs from DNA to RCB utilizing methods to ensure clonality and maximize titer. The TunaCHO℠ platform for transient production and the CHO-GSN℠ platform for stable cell line expression use the same CHO-K1 parental so products from the different platforms have similar activity & post-translational modification (PTM) profiles.

Developed from the same CHO-K1 parental cell line as our TunaCHOSM transient production system, Curia offers the CHO-GSNSM stable cell line expression platform for the production of the proteins and antibodies.

The CHO-GSNSM platform provides a glutamine synthetase (GS) knockout cell line for the generation of a research cell bank (RCB) and future use as a manufacturing cell line for commercial products.

Curia’s CHO-GSNSM CHO-K1 GS knockout for stable cell line generation is:

  • Well characterized, providing the ability to enable a 12-month construct to clinic platform
  • Compatible with chemically defined commercial media
  • Robustly tested for bioreactor production and shear force tolerance
  • Used in 100+ pre-clinical programs and clinical trials across various protein modalities (mAb, bi-specific, fc-fusion, enzyme)
  • Cost effective with competitive with flexible licensing options compared to other premium CHO production systems

Curia’s Technological Approach

  • Electroporation to ensure efficient delivery of desired genes of interest to the cellular fabric
  • Single cell plating to isolate multiple high expressors
  • Cellular imaging to monitor proliferation of a consistent monoclonal cell line

Features

  • Stable transfections to CHO-GSNSM and CHOZN® cell lines
  • Proven stability >60 generations
  • Single cell cloning and monitoring for production of stable research cell lines
  • Documented progression of research to master cell bank implementation

Ready to develop your biologic for the clinic? Contact Curia today.